April - June 2012

June 29, 2012		Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma
June 28, 2012		Takeda Obtains "Kurumin" Certification under Act to Support Raising Next-Generations Children
June 26, 2012		Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
June 26, 2012		Takeda Announces New Assignment of Directors, Appointment of Corporate Officers and Change of Senior Leadership
June 25, 2012		Rienso® (ferumoxytol) receives European marketing authorisation for the treatment of iron deficiency anaemia in adult chronic kidney disease patients
June 25, 2012		Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for patients with Short Bowel Syndrome
June 22, 2012		Takeda Announces Change of Senior Leadership and the Establishment of New Organization
June 20, 2012		Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes
June 18, 2012		Takeda’s Exclusive Distribution of Pfizer Products in Japan
June 8, 2012		Transfer of TAK-070, a Candidate Molecule for the Treatment of Alzheimer-type Dementia, to the National University Corporation
June 5, 2012		Clinical Data Presented on Orteronel (TAK-700) without Steroids in Non-metastatic Prostate Cancer
June 5, 2012		Takeda Completes Acquisition of URL Pharma, Inc.
June 4, 2012		ASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma
May 28, 2012		AZILVA® Now Available for a Treatment of Hypertension in Japan
May 25, 2012		Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
May 24, 2012		Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes
May 24, 2012		Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting
May 21, 2012		Takeda Included in the FTSE4Good Global Index for the Eighth Consecutive Year
May 11, 2012		2012-2014 Mid-Range Plan
May 11, 2012		TAKEDA ANNOUNCES GEMINI II TRIAL OF VEDOLIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE MET PRIMARY ENDPOINTS OF IMPROVEMENT IN CLINICAL REMISSION IN INDUCTION AND MAINTENANCE PHASES
May 7, 2012		Takeda Submitted a Request for Reconsideration to the National Tax Tribunal Relating to the Correction Notice on Transfer Pricing
April 26, 2012		Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone
April 25, 2012		OMONTYS® (PEGINESATIDE) INJECTION NOW AVAILABLE FOR ADULT CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON DIALYSIS IN THE UNITED STATES
April 23, 2012		Takeda and AMAG Receive A Positive CHMP Opinion in Europe for Rienso® (ferumoxytol) for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients
April 11, 2012		Takeda to Acquire URL Pharma
April 6, 2012		Takeda Announces the Conclusion of Reinvestigation Relating to the Correction Notice on Transfer Pricing
April 4, 2012		Open-Source Drug Research Consortium Draws a Major New Champion